Your browser doesn't support javascript.
Effects of statins on myocarditis: A review of underlying molecular mechanisms.
Parsamanesh, Negin; Karami-Zarandi, Morteza; Banach, Maciej; Penson, Peter E; Sahebkar, Amirhossein.
  • Parsamanesh N; Department of Molecular Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
  • Karami-Zarandi M; Department of Molecular Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
  • Banach M; Department of Hypertension, WAM University Hospital in Lodz, Medical University of Lodz, Zeromskiego 113, Lodz, Poland; Polish Mother's Memorial Hospital Research Institute (PMMHRI), Lodz, Poland. Electronic address: maciej.banach@iczmp.edu.pl.
  • Penson PE; School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK.
  • Sahebkar A; Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic
Prog Cardiovasc Dis ; 67: 53-64, 2021.
Article in English | MEDLINE | ID: covidwho-1091673
Semantic information from SemMedBD (by NLM)
1. Hydroxymethylglutaryl-CoA Reductase Inhibitors AFFECTS Myocarditis
Subject
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Predicate
AFFECTS
Object
Myocarditis
2. Myocarditis PROCESS_OF Persons
Subject
Myocarditis
Predicate
PROCESS_OF
Object
Persons
3. Myocarditis PREDISPOSES Cardiomyopath
Subject
Myocarditis
Predicate
PREDISPOSES
Object
Cardiomyopath
4. Prognosis bad PROCESS_OF Patients
Subject
Prognosis bad
Predicate
PROCESS_OF
Object
Patients
5. Hydroxymethylglutaryl-CoA Reductase Inhibitors PREVENTS Cardiovascular morbidity
Subject
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Predicate
PREVENTS
Object
Cardiovascular morbidity
6. Hydroxymethylglutaryl-CoA Reductase Inhibitors TREATS Myocarditis
Subject
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Predicate
TREATS
Object
Myocarditis
7. Hydroxymethylglutaryl-CoA Reductase Inhibitors AFFECTS lipid oxidation
Subject
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Predicate
AFFECTS
Object
lipid oxidation
8. Immunologic Adjuvants TREATS Inflammation
Subject
Immunologic Adjuvants
Predicate
TREATS
Object
Inflammation
9. 2019 novel coronavirus INTERACTS_WITH Myocarditis
Subject
2019 novel coronavirus
Predicate
INTERACTS_WITH
Object
Myocarditis
10. Hydroxymethylglutaryl-CoA Reductase Inhibitors AFFECTS Myocarditis
Subject
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Predicate
AFFECTS
Object
Myocarditis
11. Myocarditis PROCESS_OF Persons
Subject
Myocarditis
Predicate
PROCESS_OF
Object
Persons
12. Myocarditis PREDISPOSES Cardiomyopathy, Dilated
Subject
Myocarditis
Predicate
PREDISPOSES
Object
Cardiomyopathy, Dilated
13. Prognosis bad PROCESS_OF Patients
Subject
Prognosis bad
Predicate
PROCESS_OF
Object
Patients
14. Hydroxymethylglutaryl-CoA Reductase Inhibitors PREVENTS Cardiovascular morbidity
Subject
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Predicate
PREVENTS
Object
Cardiovascular morbidity
15. Hydroxymethylglutaryl-CoA Reductase Inhibitors TREATS Myocarditis
Subject
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Predicate
TREATS
Object
Myocarditis
16. Hydroxymethylglutaryl-CoA Reductase Inhibitors AFFECTS lipid oxidation
Subject
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Predicate
AFFECTS
Object
lipid oxidation
17. Immunologic Adjuvants TREATS Inflammation
Subject
Immunologic Adjuvants
Predicate
TREATS
Object
Inflammation
18. 2019 novel coronavirus INTERACTS_WITH Myocarditis
Subject
2019 novel coronavirus
Predicate
INTERACTS_WITH
Object
Myocarditis
ABSTRACT
Myocarditis refers to the clinical and histological characteristics of a diverse range of inflammatory cellular pathophysiological conditions which result in cardiac dysfunction. Myocarditis is a major cause of mortality in individuals less than 40 years of age and accounts for approximately 20% of cardiovascular disease (CVD) events. Myocarditis contributes to dilated cardiomyopathy in 30% of patients and can progress to cardiac arrest, which has a poor prognosis of <40% survival over 10 years. Myocarditis has also been documented after infection with SARS-CoV-2. The most commonly used lipid-lowering therapies, HMG-CoA reductase inhibitors (statins), decrease CVD-related morbidity and mortality. In addition to their lipid-lowering effects, increasing evidence supports the existence of several additional beneficial, 'pleiotropic' effects of statins. Recently, several studies have indicated that statins may attenuate myocarditis. Statins modify the lipid oxidation, inflammation, immunomodulation, and endothelial activity of the pathophysiology and have been recommended as adjuvant treatment. In this review, we focus on the mechanisms of action of statins and their effects on myocarditis, SARS-CoV-2 and CVD.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Cardiovascular Diseases / Hydroxymethylglutaryl-CoA Reductase Inhibitors / COVID-19 / Myocarditis Type of study: Experimental Studies / Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Prog Cardiovasc Dis Year: 2021 Document Type: Article Affiliation country: J.pcad.2021.02.008

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Cardiovascular Diseases / Hydroxymethylglutaryl-CoA Reductase Inhibitors / COVID-19 / Myocarditis Type of study: Experimental Studies / Prognostic study Topics: Long Covid Limits: Humans Language: English Journal: Prog Cardiovasc Dis Year: 2021 Document Type: Article Affiliation country: J.pcad.2021.02.008